When virologists at Makerere University and their international collaborators sequenced the blood sample of the Kampala index case, they were doing what modern outbreak science demands: confirm the pathogen, characterize its phylogeny, establish transmission history. What they found was both expected and alarming — expected, because Bundibugyo virus has always had a known but understudied reservoir in central Africa; alarming, because the 1.2% sequence divergence they reported in Nature Medicine this week is not just a data point. It is evidence that the reservoir is alive, diverse, and repeatedly giving rise to human cases independent of prior outbreak chains.
That finding should change how filovirus preparedness is organized. The global response framework for hemorrhagic fever outbreaks has, since 2014–2016, been shaped almost entirely by Ebola Zaire. Two vaccines now exist for Zaire ebolavirus. Monoclonal antibody cocktails — REGN-EB3, mAb114 — have changed case fatality rates in Zaire outbreaks from historical highs exceeding 70% to treated-case survival of approximately 65–67% in the pivotal PALM trial (day-28 survival of 66.5% with REGN-EB3 and 64.9% with mAb114 in the full trial population).
Bundibugyo virus has none of these. The 2026 outbreak is unfolding in the Ituri province of the DRC with a roughly 20% case fatality rate and no specific therapies to administer, no vaccine to deploy at the ring, no approved monoclonal antibody to offer severely ill patients.
This is not an accident of research neglect — it is a predictable consequence of rational resource triage. Bundibugyo virus caused only two recognized outbreaks before 2026: approximately 149 suspected cases (56 laboratory-confirmed) in 2007 and approximately 36–38 confirmed cases in 2012. The low historical burden was a defensible rationale for prioritizing Zaire ebolavirus countermeasures. The 2026 outbreak, which had already logged 676 confirmed cases and 136 deaths in the DRC — 695 total including 19 cases and 2 deaths in Uganda — as of June 10, surpassing both prior Bundibugyo outbreaks combined by more than an order of magnitude, suggests the triage calculus was wrong.
The Nature Medicine paper documenting the Uganda index case is a scientific record. It is also a clinical argument for extending the filovirus countermeasure portfolio beyond Zaire ebolavirus. That argument has now been made in blood.
— The Vital Record · Editorial
Correction — June 13, 2026: Four numerical errors corrected in this editorial. (1) The 2026 outbreak case and death counts as of June 10 have been updated from 635 cases/127 deaths to 676 confirmed cases/136 deaths in the DRC (695 total/138 deaths including Uganda), per WHO DON606. (2) The 2007 Bundibugyo outbreak figure has been clarified: 149 was the total suspected case count; 56 were laboratory-confirmed. (3) The claim that monoclonal antibody treatment brings Zaire ebolavirus survival “to 70% or better” has been corrected to “approximately 65–67%,” reflecting the PALM trial’s overall day-28 survival rates of 66.5% (REGN-EB3) and 64.9% (mAb114); the 70%+ figure reflects low-viral-load subgroups, not the full trial population. (4) The 2012 Bundibugyo outbreak figure has been revised from 52 to approximately 36–38 confirmed cases, consistent with WHO DON records from the Isiro outbreak. The central argument of this editorial is unaffected by these corrections.